Edesa Biotech Inc Market Cap ($30.81 Million)
Market Cap & Net Worth: Edesa Biotech Inc (EDSA)
Edesa Biotech Inc market cap. Edesa Biotech Inc (NASDAQ:EDSA) has a market capitalization of $30.81 Million ($30.81 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23461 globally and #5119 in its home market, demonstrating a -11.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Edesa Biotech Inc's stock price $2.28 by its total outstanding shares 13511531 (13.51 Million). Also see Edesa Biotech Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Edesa Biotech Inc Market Cap History (2015–2026)
Edesa Biotech Inc market cap history from 2015 to 2026. Data shows change from $25.78 Billion to $30.81 Million (-46.16% CAGR). Check current stock price of Edesa Biotech Inc for real-time trading data and today's change.
Index Memberships
Edesa Biotech Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #662 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2195 of 3165 |
Weight: Edesa Biotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Edesa Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Edesa Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Edesa Biotech Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1064978.87x
Edesa Biotech Inc's market cap is 1064978.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $8.06 Billion | $1.27 Million | -$5.03 Million | 6341.14x | N/A |
| 2017 | $3.22 Billion | $228.29K | -$5.03 Million | 14094.70x | N/A |
| 2018 | $516.41 Million | $211.85K | -$5.04 Million | 2437.64x | N/A |
| 2019 | $387.78 Million | $410.87K | -$2.72 Million | 943.80x | N/A |
| 2020 | $401.97 Million | $328.80K | -$6.36 Million | 1222.53x | N/A |
| 2021 | $532.49 Million | $500.00 | -$13.34 Million | 1064978.87x | N/A |
Competitor Companies of EDSA by Market Capitalization
Companies near Edesa Biotech Inc in the global market cap rankings as of November 4, 2026. Also see EDSA current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Edesa Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Edesa Biotech Inc (2015–2026)
Market capitalization of Edesa Biotech Inc from 2015 to today. Between 2015 and today, Edesa Biotech Inc's market cap moved from $25.78 Billion to $ 30.81 Million, with a yearly change of -46.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $30.81 Million | +60.56% |
| 2025 | $19.19 Million | -15.48% |
| 2024 | $22.70 Million | -63.24% |
| 2023 | $61.75 Million | -69.78% |
| 2022 | $204.29 Million | -61.63% |
| 2021 | $532.49 Million | +32.47% |
| 2020 | $401.97 Million | +3.66% |
| 2019 | $387.78 Million | -24.91% |
| 2018 | $516.41 Million | -83.95% |
| 2017 | $3.22 Billion | -60.10% |
| 2016 | $8.06 Billion | -68.72% |
| 2015 | $25.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Edesa Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.81 Million USD |
| MoneyControl | $30.81 Million USD |
| MarketWatch | $30.81 Million USD |
| marketcap.company | $30.81 Million USD |
| Reuters | $30.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more